FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385871686> ?p ?o ?g. }

• W4385871686 endingPage "102154" @default.
• W4385871686 startingPage "102154" @default.
• W4385871686 abstract "BackgroundCase reports suggest that SARS-CoV-2 infection could lead to immune dysregulation and trigger autoimmunity while COVID-19 vaccination is effective against severe COVID-19 outcomes. We aim to examine the association between COVID-19 and development of autoimmune diseases (ADs), and the potential protective effect of COVID-19 vaccination on such an association.MethodsA retrospective cohort study was conducted in Hong Kong between 1 April 2020 and 15 November 2022. COVID-19 was confirmed by positive polymerase chain reaction or rapid antigen test. Cox proportional hazard regression with inverse probability of treatment weighting was applied to estimate the risk of incident ADs following COVID-19. COVID-19 vaccinated population was compared against COVID-19 unvaccinated population to examine the protective effect of COVID-19 vaccination on new ADs.FindingsThe study included 1,028,721 COVID-19 and 3,168,467 non-COVID individuals. Compared with non-COVID controls, patients with COVID-19 presented an increased risk of developing pernicious anaemia [adjusted Hazard Ratio (aHR): 1.72; 95% Confidence Interval (CI): 1.12–2.64]; spondyloarthritis [aHR: 1.32 (95% CI: 1.03–1.69)]; rheumatoid arthritis [aHR: 1.29 (95% CI: 1.09–1.54)]; other autoimmune arthritis [aHR: 1.43 (95% CI: 1.33–1.54)]; psoriasis [aHR: 1.42 (95% CI: 1.13–1.78)]; pemphigoid [aHR: 2.39 (95% CI: 1.83–3.11)]; Graves' disease [aHR: 1.30 (95% CI: 1.10–1.54)]; anti-phospholipid antibody syndrome [aHR: 2.12 (95% CI: 1.47–3.05)]; immune mediated thrombocytopenia [aHR: 2.1 (95% CI: 1.82–2.43)]; multiple sclerosis [aHR: 2.66 (95% CI: 1.17–6.05)]; vasculitis [aHR: 1.46 (95% CI: 1.04–2.04)]. Among COVID-19 patients, completion of two doses of COVID-19 vaccine shows a decreased risk of pemphigoid, Graves' disease, anti-phospholipid antibody syndrome, immune-mediated thrombocytopenia, systemic lupus erythematosus and other autoimmune arthritis.InterpretationOur findings suggested that COVID-19 is associated with an increased risk of developing various ADs and the risk could be attenuated by COVID-19 vaccination. Future studies investigating pathology and mechanisms would be valuable to interpreting our findings.FundingSupported by RGC Collaborative Research Fund (C7154-20GF)." @default.
• W4385871686 created "2023-08-17" @default.
• W4385871686 creator A5000640938 @default.
• W4385871686 creator A5019481801 @default.
• W4385871686 creator A5022169204 @default.
• W4385871686 creator A5022905161 @default.
• W4385871686 creator A5025936391 @default.
• W4385871686 creator A5041610413 @default.
• W4385871686 creator A5043051253 @default.
• W4385871686 creator A5044023540 @default.
• W4385871686 creator A5048726723 @default.
• W4385871686 creator A5050655280 @default.
• W4385871686 creator A5063190766 @default.
• W4385871686 creator A5079729727 @default.
• W4385871686 creator A5090788920 @default.
• W4385871686 date "2023-09-01" @default.
• W4385871686 modified "2023-10-18" @default.
• W4385871686 title "Risk of autoimmune diseases following COVID-19 and the potential protective effect from vaccination: a population-based cohort study" @default.
• W4385871686 cites W2100779666 @default.
• W4385871686 cites W2160840037 @default.
• W4385871686 cites W2754566810 @default.
• W4385871686 cites W2791415378 @default.
• W4385871686 cites W2967488951 @default.
• W4385871686 cites W3037185429 @default.
• W4385871686 cites W3039199524 @default.
• W4385871686 cites W3042549470 @default.
• W4385871686 cites W3042907391 @default.
• W4385871686 cites W3045821938 @default.
• W4385871686 cites W3082843346 @default.
• W4385871686 cites W3096975836 @default.
• W4385871686 cites W3134175354 @default.
• W4385871686 cites W3152668629 @default.
• W4385871686 cites W3169276025 @default.
• W4385871686 cites W3186735486 @default.
• W4385871686 cites W3191395227 @default.
• W4385871686 cites W3200448018 @default.
• W4385871686 cites W3205044984 @default.
• W4385871686 cites W4200092905 @default.
• W4385871686 cites W4200255055 @default.
• W4385871686 cites W4200577699 @default.
• W4385871686 cites W4220971349 @default.
• W4385871686 cites W4221036039 @default.
• W4385871686 cites W4221088496 @default.
• W4385871686 cites W4224307955 @default.
• W4385871686 cites W4224950216 @default.
• W4385871686 cites W4226062220 @default.
• W4385871686 cites W4226192094 @default.
• W4385871686 cites W4226318522 @default.
• W4385871686 cites W4281552311 @default.
• W4385871686 cites W4285606826 @default.
• W4385871686 cites W4286685017 @default.
• W4385871686 cites W4313252629 @default.
• W4385871686 cites W4316687819 @default.
• W4385871686 doi "https://doi.org/10.1016/j.eclinm.2023.102154" @default.
• W4385871686 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37637754" @default.
• W4385871686 hasPublicationYear "2023" @default.
• W4385871686 type Work @default.
• W4385871686 citedByCount "3" @default.
• W4385871686 countsByYear W43858716862023 @default.
• W4385871686 crossrefType "journal-article" @default.
• W4385871686 hasAuthorship W4385871686A5000640938 @default.
• W4385871686 hasAuthorship W4385871686A5019481801 @default.
• W4385871686 hasAuthorship W4385871686A5022169204 @default.
• W4385871686 hasAuthorship W4385871686A5022905161 @default.
• W4385871686 hasAuthorship W4385871686A5025936391 @default.
• W4385871686 hasAuthorship W4385871686A5041610413 @default.
• W4385871686 hasAuthorship W4385871686A5043051253 @default.
• W4385871686 hasAuthorship W4385871686A5044023540 @default.
• W4385871686 hasAuthorship W4385871686A5048726723 @default.
• W4385871686 hasAuthorship W4385871686A5050655280 @default.
• W4385871686 hasAuthorship W4385871686A5063190766 @default.
• W4385871686 hasAuthorship W4385871686A5079729727 @default.
• W4385871686 hasAuthorship W4385871686A5090788920 @default.
• W4385871686 hasBestOaLocation W43858716861 @default.
• W4385871686 hasConcept C126322002 @default.
• W4385871686 hasConcept C167135981 @default.
• W4385871686 hasConcept C201903717 @default.
• W4385871686 hasConcept C203014093 @default.
• W4385871686 hasConcept C207103383 @default.
• W4385871686 hasConcept C22070199 @default.
• W4385871686 hasConcept C2777575956 @default.
• W4385871686 hasConcept C2908647359 @default.
• W4385871686 hasConcept C44249647 @default.
• W4385871686 hasConcept C50382708 @default.
• W4385871686 hasConcept C71924100 @default.
• W4385871686 hasConcept C99454951 @default.
• W4385871686 hasConceptScore W4385871686C126322002 @default.
• W4385871686 hasConceptScore W4385871686C167135981 @default.
• W4385871686 hasConceptScore W4385871686C201903717 @default.
• W4385871686 hasConceptScore W4385871686C203014093 @default.
• W4385871686 hasConceptScore W4385871686C207103383 @default.
• W4385871686 hasConceptScore W4385871686C22070199 @default.
• W4385871686 hasConceptScore W4385871686C2777575956 @default.
• W4385871686 hasConceptScore W4385871686C2908647359 @default.
• W4385871686 hasConceptScore W4385871686C44249647 @default.
• W4385871686 hasConceptScore W4385871686C50382708 @default.
• W4385871686 hasConceptScore W4385871686C71924100 @default.
• W4385871686 hasConceptScore W4385871686C99454951 @default.

• next